Multinational anticancer corporations Beigene announced on the 28th that it has changed its name to "BeOne Medicines Ltd." In addition, it plans to change its corporate registration location to Switzerland and launch anew.
Founder and Chief Executive Officer (CEO) John Oyler said, "BeOne is a declaration of identity beyond a mere name change, meaning 'united we conquer cancer.'" He noted that with the remarkable growth of its blood cancer treatment BRUKINSA and the expanded potential of the immune anticancer drug "tislelizumab," along with over 50 anticancer pipelines, they are already opening a new era.
The new BeOne corporate brand will gradually be applied across its business operations on six continents over the coming months. The domestic corporation Beigene Korea will also change its corporate name to "BeOne Medicines Korea" effective June 30.
The representative product, blood cancer treatment "BRUKINSA," is recording the highest market share for new patients in the United States. BCL2 inhibitor (sonrotoclax) and BTK protein degrader (BGB-16673) are also considered key products in the blood cancer lineup. BeOne Medicines is expanding its product line into solid tumors such as breast cancer, lung cancer, and gastrointestinal cancer. They plan to set a new standard for next-generation anticancer treatments by utilizing a platform based on multi-specific antibodies, protein degraders, and antibody-drug conjugate (ADC) technology.
Currently, a clinical development organization of 3,700 personnel is conducting or preparing for clinical trials in more than 45 countries. Additionally, they are expanding production capacity centered around an $800 million R&D and production hub located at the Princeton West Innovation Campus in Hopewell, New Jersey.